Kwality Pharmaceuticals Limited

BSE: KPL539997ISIN INE552U01010

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹3,744.55+115.10 (+3.17%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹3,866.55
52W low: ₹828.80
Off 52W high: -3.16%
1M return: +2.83%
3M return: +46.48%
6M return: +116.96%
1Y return: +316.89%
20D avg volume: 4,423
50 DMA: ₹3,522.47
200 DMA: ₹2,359.03

Key ratios Consolidated

Market cap: ₹3,885 Cr
Current price: ₹3,744.55
52W high / low: ₹3,866.55 / ₹828.80
Face value: ₹10.00
P/E: 47.94
P/B: 11.72
EPS (TTM): ₹78.11
Book value / share: ₹319.57
ROE: —
ROCE: 27.40%
Operating margin: —
Net margin: —
Debt / equity: 0.40
Net debt: ₹129.72 Cr
Interest cover: 9.16
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 186.2 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	162.35	157.11	123.44	111.05	111.48	115.68	84.41	90.03	80.08	91.98	78.09	69.65
	0.62	1.06	0.53	0.90	0.38	0.77	0.66	0.22	0.28	0.58	0.62	0.23
	162.97	158.17	123.97	111.95	111.86	116.44	85.06	90.26	80.36	92.56	78.71	69.88
	128.99	126.50	100.79	93.50	94.83	97.37	73.67	77.70	69.24	79.48	68.96	61.72
	85.34	79.68	57.11	54.05	49.98	52.29	36.78	38.91	37.43	47.73	39.54	33.06
	0.47	6.03	2.32	1.02	7.98	6.50	1.93	4.71	2.77	—	0.63	0.12
	14.74	14.22	14.36	13.31	12.15	12.68	11.07	10.30	9.72	9.00	8.01	7.92
	2.66	2.89	2.48	2.84	2.76	2.49	2.20	2.71	2.48	3.06	2.73	2.41
	4.99	5.26	4.82	4.96	4.76	5.09	4.56	4.62	4.03	5.07	4.82	4.88
	19.16	17.46	20.03	17.76	17.11	16.32	17.11	16.12	13.99	16.32	13.45	12.35
	33.99	31.67	23.18	18.45	17.03	19.07	11.39	12.55	11.12	13.08	9.75	8.17
	0.00	0.00	-0.83	0.00	0.00	0.00	0.00	0.00	0.00	-7.10	0.00	0.00
	33.99	31.67	22.35	18.45	17.03	19.07	11.39	12.55	11.12	5.99	9.75	8.17
	8.37	6.36	6.35	4.33	5.11	4.59	2.87	4.10	2.77	1.75	2.07	1.95
	25.62	25.31	16.00	14.12	11.92	14.48	8.52	8.46	8.35	4.24	7.68	6.21
	24.69	24.39	15.42	13.60	11.49	13.95	8.21	8.15	8.04	4.08	7.39	5.99
Key metrics
	41.64	39.82	29.65	26.25	24.55	26.65	18.15	19.88	17.63	14.12	17.30	15.46
	25.60%	25.30%	24.00%	23.60%	22.00%	23.00%	21.50%	22.10%	22.00%	15.40%	22.20%	22.20%
	15.80%	16.10%	13.00%	12.70%	10.70%	12.50%	10.10%	9.40%	10.40%	4.60%	9.80%	8.90%
	—	9.40%	—	6.90%	—	7.80%	—	—	—	—	—	—
	45.60%	35.80%	46.20%	23.30%	39.20%	25.80%	8.10%	29.30%	—	—	—	—
	114.90%	74.80%	87.80%	66.90%	42.80%	241.50%	10.90%	36.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	553.95	503.08	370.20	307.17	251.03	456.19
	3.11	2.86	1.92	1.83	2.94	3.51
	557.06	505.94	372.12	309.00	253.97	459.70
	449.78	415.62	317.98	270.80	211.87	298.13
	276.18	240.81	165.41	153.81	113.22	199.31
	9.84	17.35	15.90	0.85	0.04	3.80
	56.63	54.04	43.78	32.56	29.96	20.15
	10.87	10.97	9.88	10.39	6.02	2.92
	20.03	19.81	18.29	19.56	14.96	10.69
	74.41	72.36	63.54	55.11	50.86	63.77
	107.29	90.32	54.14	38.20	42.10	161.57
	-0.83	-0.83	0.00	-7.10	-16.53	0.00
	106.46	89.49	54.14	31.10	25.57	161.57
	25.41	22.15	14.34	7.48	6.29	41.63
	81.05	67.35	39.80	23.62	19.28	119.94
	78.10	64.90	38.36	22.76	18.16	—
Key metrics
	137.36	120.27	82.31	61.05	46.55	175.18
	24.80%	23.90%	22.20%	19.90%	18.50%	38.40%
	14.63%	13.40%	10.80%	7.70%	7.70%	26.30%
	—	27.40%	23.00%	—	—	—
	37.94%	35.90%	20.50%	22.40%	-45.00%	—
	86.84%	69.20%	68.50%	22.50%	-83.90%	—
	—	-28.01	29.43	—	—	—
	—	0.25	1.32	—	—	—
	—	0.40	0.43	—	—	—
	—	129.72	100.43	—	—	—
	—	186.2	179.4	—	—	—
Balance sheet
	—	592.21	447.27	—	—	—
	—	405.68	283.78	—	—	—
	—	0.74	12.02	—	—	—
	—	280.05	154.31	—	—	—
	—	78.25	83.47	—	—	—
	—	34.96	18.46	—	—	—
	—	149.73	143.98	—	—	—
	—	101.69	55.79	—	—	—
	—	225.52	169.51	—	—	—
	—	130.46	112.45	—	—	—
	—	101.06	97.33	—	—	—
	—	29.40	15.12	—	—	—
	—	329.92	262.40	—	—	—
Cash flow
	—	16.59	52.72	—	—	—
	—	-34.91	-28.52	—	—	—
	—	7.04	-14.44	—	—	—
	—	44.60	23.29	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	162.35	156.82	123.44	111.31	111.48	115.68	84.41	90.03	80.08	91.98	78.09	69.65
	0.62	1.06	0.53	0.90	0.38	0.77	0.66	0.22	0.28	0.58	0.62	0.23
	162.97	157.88	123.97	112.21	111.86	116.44	85.06	90.26	80.36	92.56	78.71	69.88
	128.98	126.23	100.79	93.76	94.81	97.35	73.65	77.67	69.22	79.22	68.94	61.67
	85.34	79.68	57.11	54.05	49.98	52.29	36.79	38.91	37.43	47.73	39.54	33.06
	0.47	6.03	2.32	1.02	7.98	6.50	1.93	4.71	2.77	—	0.63	0.12
	14.74	14.22	14.36	13.31	12.15	12.68	11.07	10.30	9.72	8.98	8.00	7.92
	2.66	2.89	2.48	2.84	2.76	2.49	2.20	2.71	2.48	3.06	2.73	2.41
	4.99	5.26	4.82	4.96	4.76	5.08	4.55	4.61	4.02	5.04	4.81	4.88
	19.16	17.46	20.03	17.76	17.11	16.31	17.11	16.10	13.99	16.10	13.44	12.32
	33.99	31.65	23.18	18.45	17.04	19.09	11.41	12.58	11.14	13.34	9.78	8.21
	0.00	0.00	-0.83	0.00	0.00	0.00	—	—	—	-7.10	—	—
	33.99	31.65	22.35	18.45	17.04	19.09	11.41	12.58	11.14	6.24	9.78	8.21
	8.37	6.36	6.35	4.33	5.11	4.59	2.87	4.10	2.77	1.75	2.07	1.95
	25.63	25.29	16.01	14.12	11.93	14.50	8.54	8.48	8.37	4.50	7.70	6.26
	24.70	24.37	15.43	13.60	11.50	13.97	8.23	8.18	8.06	4.33	7.42	6.03
Key metrics
	41.64	39.80	29.65	26.25	24.56	26.66	18.16	19.90	17.64	14.34	17.32	15.50
	25.60%	25.40%	24.00%	23.60%	22.00%	23.00%	21.50%	22.10%	22.00%	15.60%	22.20%	22.30%
	15.80%	16.10%	13.00%	12.70%	10.70%	12.50%	10.10%	9.40%	10.50%	4.90%	9.90%	9.00%
	—	9.30%	—	6.90%	—	7.70%	—	—	—	—	—	—
	45.60%	35.60%	46.20%	23.60%	39.20%	25.80%	8.10%	29.30%	—	—	—	—
	114.80%	74.40%	87.50%	66.50%	42.50%	222.20%	10.90%	35.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	553.92	503.06	370.20	307.17	251.00	456.13
	3.11	2.86	1.92	1.83	2.94	3.51
	557.03	505.92	372.12	309.00	253.94	459.64
	449.76	415.60	317.89	270.44	211.65	297.97
	276.18	240.81	165.41	153.81	113.22	199.31
	9.84	17.35	15.90	0.85	0.04	3.80
	56.63	54.04	43.76	32.53	29.90	20.09
	10.87	10.97	9.88	10.39	6.02	2.92
	20.03	19.79	18.26	19.51	14.92	10.64
	74.41	72.36	63.51	54.83	50.74	63.72
	107.27	90.32	54.23	38.57	42.29	161.68
	-0.83	-0.83	0.00	-7.10	-16.53	—
	106.44	89.49	54.23	31.47	25.76	161.68
	25.41	22.15	14.34	7.48	6.29	41.63
	81.05	67.35	39.89	23.98	19.47	120.05
	78.10	64.90	38.44	23.11	18.45	—
Key metrics
	137.34	120.25	82.37	61.37	46.70	175.24
	24.79%	23.90%	22.30%	20.00%	18.60%	38.40%
	14.63%	13.40%	10.80%	7.80%	7.80%	26.30%
	—	27.10%	22.80%	—	—	—
	37.93%	35.90%	20.50%	22.40%	-45.00%	—
	86.54%	68.80%	66.30%	23.20%	-83.80%	—
	—	-27.60	29.86	—	—	—
	—	0.25	1.32	—	—	—
	—	0.39	0.42	—	—	—
	—	129.78	100.90	—	—	—
	—	187.0	181.0	—	—	—
Balance sheet
	—	595.66	450.72	—	—	—
	—	406.79	284.90	—	—	—
	—	0.68	11.55	—	—	—
	—	281.22	155.90	—	—	—
	—	78.25	83.47	—	—	—
	—	34.96	18.46	—	—	—
	—	148.52	142.76	—	—	—
	—	101.69	55.79	—	—	—
	—	225.52	169.51	—	—	—
	—	130.46	112.45	—	—	—
	—	101.06	97.33	—	—	—
	—	29.40	15.12	—	—	—
	—	333.37	265.84	—	—	—
Cash flow
	—	17.00	52.77	—	—	—
	—	-34.91	-28.13	—	—	—
	—	7.04	-14.44	—	—	—
	—	44.60	22.91	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +26.08%
Sales CAGR 5Y: —
Profit CAGR 3Y: +51.24%
Profit CAGR 5Y: —
Sales YoY (TTM): +37.93%
Profit YoY (TTM): +86.54%

Consolidated

Sales CAGR 3Y: +26.08%
Sales CAGR 5Y: —
Profit CAGR 3Y: +51.73%
Profit CAGR 5Y: —
Sales YoY (TTM): +37.94%
Profit YoY (TTM): +86.84%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 54.86%

Quarter	September 2026	June 2026
Promoter %	54.86%	54.86%

Holder	Type	Holding	Previous	Change
RAMESH ARORA	Promoter	26.03%	26.03%	0.00%
AJAY ARORA	Promoter	13.60%	13.60%	0.00%
ADITYA ARORA	Promoter Group	11.96%	11.96%	0.00%
DEEPAK BANSAL	Public	8.16%	8.39%	-0.23%
MANOHAR DEVABHAKTUNI	Public	4.98%	4.98%	0.00%
KADAYAM RAMNATHAN BHARAT	Public	1.98%	1.98%	0.00%
ARK GLOBAL EMERGING COMPANIES, LP	Public	1.84%	2.11%	-0.27%
JANI BHASHA SHAIK	Public	1.45%	1.45%	0.00%
DHEERAJ KUMAR LOHIA	Public	1.37%	1.66%	-0.29%
ANJU ARORA	Promoter Group	1.31%	1.31%	0.00%
ONKAR SINGH	Public	1.09%	1.09%	0.00%
GEETA ARORA	Promoter Group	1.07%	1.07%	0.00%
JUGAL KISHORE HUF	Promoter Group	0.89%	0.89%	0.00%
AARTI BAJAJ	Promoter Group	0.00%	0.00%	0.00%
SACHIN SETH	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Kwality Pharmaceuticals Limited	3,885	3,744.55	47.94	27.40%	+37.94% TTM	+86.84% TTM	+316.89%

Filings & corporate actions

Recent announcements

EU-GMP Approval from Hungary for Cephalosporin and Oncology Facilities4 Nov 2026 · Company Update / General
Acquisition of Land for Manufacturing Expansion at Amritsar19 Oct 2026 · Company Update / General
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30-09-202610 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Regularization of appointment of Mr Swanith Kapoor as Director and reappointment of Mr Aditya Arora as WTD of the company2 Sep 2026 · Company Update / Change in Management
SCRUTINIZER REPORT OF AGM E-VOTING IS ATTACHED2 Sep 2026 · AGM/EGM / AGM
Proceedings of 43rd Annual General Meeting attached herewith.31 Aug 2026 · AGM/EGM / AGM
Newspaper Publication of Unaudited Financial Results for the quarter ended June 30, 2026.13 Aug 2026 · Company Update / Newspaper Publication
Newspaper Publication of Notice of 43rd Annual General Meeting.12 Aug 2026 · Company Update / Newspaper Publication
Outcome of Investors/Analysts Meeting held on August 10, 202612 Aug 2026 · Company Update / Analyst / Investor Meet
Transcript of Earnings Conference Call - Q1FY2712 Aug 2026 · Company Update / Earnings Call Transcript
Transcript of Earnings Conference Call - Q1FY2712 Aug 2026 · Company Update / Earnings Call Transcript
Investor Presentation for quarter ended June 30, 2026.10 Aug 2026 · Company Update / Investor Presentation
Financial Results for Quarter Ended June 30, 2026.10 Aug 2026 · Result / Financial Results
Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 201510 Aug 2026 · Board Meeting / Outcome of Board Meeting
NOTICE OF 43RD AGM IS ENCLOSED9 Aug 2026 · AGM/EGM / AGM
Pursuant to Regulations 30 and 34 of the SEBI (LODR) Regulations, 2015, as amended ('' Listing Regulations''), please find attached herewith the Annual Report of the Company for the FY ....9 Aug 2026 · Others / Reg. 34 (1) Annual Report
Intimation of Book Closure.8 Aug 2026 · Company Update / General
Intimation of 43rd AGM8 Aug 2026 · Company Update / General
This is to inform you, pursuant to Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Board of Directors ....8 Aug 2026 · Others / Outcome without intimation
Intimation of Earnings Conference Call for Q1 FY 2026-274 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of Earnings Conference Call for Q1 FY 2026-274 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of Earnings Conference Call for Q1 FY 2026-274 Aug 2026 · Company Update / Analyst / Investor Meet
Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve the Standalone and ....3 Aug 2026 · Board Meeting / Board Meeting
Kwality Pharmaceuticals receives CDSCO Nod to Initiate Preclinical Pilot Batches of Pembroluzimab24 Jul 2026 · Company Update / General
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30-06-2026.13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window29 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Resignation of Mr. Kartik Kapur, Independent Director of the Company.2 Jun 2026 · Company Update / Resignation of Director
Appointment of Mr. Swanith Kapoor as Additional (Non-Executive, Independent) Director and Resignation of Mr. Kartik Kapur, Independent Director of the Company.2 Jun 2026 · Company Update / Change in Management
Annual Secretarial Compliance Report for the year ended 31-03-2026 is enclosed herewith30 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Audio recording of quarterly earning conference call28 May 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication of Audited Financial Results for the quarter and year ended March 31, 2026.22 May 2026 · Company Update / Newspaper Publication
Transcript of Earning Conference Call of Q4FY2026.21 May 2026 · Company Update / Earnings Call Transcript
Investor Presentation for the quarter and year ended 31st March, 2026.19 May 2026 · Company Update / Investor Presentation
Audited Financial Results for the quarter and year ended 31st March, 2026.19 May 2026 · Result / Financial Results
Audited Financial Results for the quarter and year ended 31st March, 202619 May 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Analysts/Investors Conference Call to be held on May 19, 2026 at 5:00 P.M. to discuss Q4 FY26 financial results.14 May 2026 · Company Update / Analyst / Investor Meet
Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve the Standalone & Consolidated ....8 May 2026 · Board Meeting / Board Meeting
Intimation of Revision in Credit Rating8 May 2026 · Company Update / Credit Rating
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....30 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Board meetings

10 Aug 2026 Board Meeting - Financial Results